Health Care • Biotechnology: Pharmaceutical Preparations
$0.40 ▼ -0.03
(-5.97%)
MKT CAP: $52.4M • VOL: 848.0K
52W L $0 52W H $1
ROARABLE / RQD
D- • 41/100
PIOTROSKI
2 / 9
ONCY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $80.4M | $71.5M |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$28.7M | -$25.5M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$28.8M | -$22.8M |
| EBITDA (Normalized) | -$28.7M | -$25.4M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$20.1M | -$19.9M |
| Capital Expenditures (CapEx) | $6.0K | $174.0K |
| Free Cash Flow (FCF) | -$20.1M | -$20.1M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $5.2M | $11.1M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$3.8M | $3.3M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ONCY.